Acasti Pharma Net Income 2014-2023 | ACST
Acasti Pharma net income from 2014 to 2023. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Acasti Pharma Annual Net Income
(Millions of US $) |
| 2023 |
$-42 |
| 2022 |
$-10 |
| 2021 |
$-20 |
| 2020 |
$-26 |
| 2019 |
$-39 |
| 2018 |
$-17 |
| 2017 |
$-8 |
| 2016 |
$-5 |
| 2015 |
$-5 |
| 2015 |
$ |
| 2014 |
$-11 |
| 2014 |
$ |
| 2013 |
$-7 |
| 2013 |
$ |
Acasti Pharma Quarterly Net Income
(Millions of US $) |
| 2023-12-31 |
$-2 |
| 2023-09-30 |
$-3 |
| 2023-06-30 |
$-4 |
| 2023-03-31 |
$-29 |
| 2022-12-31 |
$-4 |
| 2022-09-30 |
$-5 |
| 2022-06-30 |
$-5 |
| 2022-03-31 |
$-4 |
| 2021-12-31 |
$-4 |
| 2021-09-30 |
$1 |
| 2021-06-30 |
$-3 |
| 2021-03-31 |
$-6 |
| 2020-12-31 |
$-3 |
| 2020-09-30 |
$-6 |
| 2020-06-30 |
$-5 |
| 2020-03-31 |
$17 |
| 2019-12-31 |
$-12 |
| 2019-09-30 |
$-21 |
| 2019-06-30 |
$-9 |
| 2019-03-31 |
$-13 |
| 2018-12-31 |
$-3 |
| 2018-09-30 |
$-17 |
| 2018-06-30 |
$-6 |
| 2018-03-31 |
$-6 |
| 2017-12-31 |
$-5 |
| 2017-09-30 |
$-4 |
| 2017-06-30 |
$-2 |
| 2017-02-28 |
$-2 |
| 2016-11-30 |
$-2 |
| 2016-08-31 |
$-2 |
| 2016-05-31 |
$-2 |
| 2016-03-31 |
$-2 |
| 2016-02-29 |
|
| 2015-12-31 |
$-2 |
| 2015-09-30 |
$-1 |
| 2015-06-30 |
$-1 |
| 2015-03-31 |
$-2 |
| 2014-12-31 |
$3 |
| 2014-09-30 |
$-3 |
| 2014-06-30 |
$1 |
| 2014-03-31 |
$-3 |
| 2014-02-28 |
|
| 2013-12-31 |
$-4 |
| 2013-09-30 |
$-3 |
| 2013-06-30 |
$-2 |
| 2013-03-31 |
$-2 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.030B |
$0.000B |
|
Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada.
|
